Bismuth Subgallate
drug drugOn this page
Also known as Basic bismuth gallateGallic acid bismuth basic saltSID29218038SID144205941BISMUTH-SUBGALLATE
Summary
Bismuth Subgallate (CHEMBL1592101) is an approved small molecule; indicated across 1 condition.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 1 condition
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1592101 |
| Name | Bismuth Subgallate |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Basic bismuth gallate, Bismuth subgallate, Gallic acid bismuth basic salt, SID29218038, SID144205941, BISMUTH SUBGALLATE, BISMUTH-SUBGALLATE, bismuth-subgallate
Targets
Targets
Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| LMNA | 6.1 | Potency | 794.3 | nM | CHEMBL_ACT_3632508 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.
Clinical trials
Total trials: 0.
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.